In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk Pharma AG

Latest From Novo Nordisk Pharma AG

Taking On Obesity The Hard Way

Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations. 

Clinical Trials Companies

US FDA Commissioner Pushes Real-World Evidence To Guide Use Of Alzheimer’s, Obesity Drugs

‘We’ve got these enormous markets,’ Rob Califf says. ‘Should 65% of the US population be treated with obesity drugs?’

Real-World Evidence Neurology

Obesity Drug Coverage In Employer-Sponsored Plans On Slow Build Trajectory, Survey Finds

Large employer plan sponsors split on whether to cover GLP-1 drugs for weight loss, according to a recent survey.

Reimbursement Commercial

Informed Consent Final Guidance: Drug Makers Get Some Tweaks But Not Every Change They Wanted

From when the consent process starts to how to handle standard of care discussions, US FDA’s long-awaited final guidance on informed consent reflects some changes sought by sponsors. More changes may be in store soon due to revisions of the Common Rule.

Guidance Documents Clinical Trials
See All

Company Information